Insmed To Present at March 2025 Investor Conferences

Rhea-AI Summary

Insmed (Nasdaq: INSM), a global biopharmaceutical company, has announced its management's upcoming presentations at two major investor conferences in March 2025. The company will present at the 45th Annual TD Cowen Healthcare Conference in Boston on March 3, 2025, at 9:10 a.m. ET, and at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2025, at 8:00 a.m. ET.

Both presentations will be available through live webcasts accessible via the investor relations section of Insmed's website at www.insmed.com. The webcasts will remain archived for 30 days after the events conclude.

BRIDGEWATER, N.J., Feb. 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:

• 45^th Annual TD Cowen Healthcare Conference in Boston, on Monday, March 3, 2025, at 9:10 a.m. ET.
  
  
• Leerink Partners Global Healthcare Conference in Miami, on Tuesday, March 11, 2025, at 8:00 a.m. ET.

These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.

Contact:

Investors: 

Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com 

Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com 

Gianna De Palma
Manager, Investor Relations
(973) 886-2236
gianna.depalma@insmed.com 

Media:

Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com  

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-march-2025-investor-conferences-302369513.html

SOURCE Insmed Incorporated

FAQ

When is Insmed (INSM) presenting at the TD Cowen Healthcare Conference in March 2025?

Insmed will present at the TD Cowen Healthcare Conference in Boston on Monday, March 3, 2025, at 9:10 a.m. ET.

What time is Insmed's (INSM) presentation at the Leerink Partners Conference in March 2025?

Insmed will present at the Leerink Partners Global Healthcare Conference in Miami on Tuesday, March 11, 2025, at 8:00 a.m. ET.

How long will the webcasts of Insmed's (INSM) March 2025 investor presentations be available?

The webcasts will be archived and available for 30 days following the conclusion of each live event.

Where can investors access the webcasts of Insmed's (INSM) March 2025 conference presentations?

Investors can access the webcasts through the investor relations section of Insmed's website at www.insmed.com.